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Patient safety has received unprecedented attention over the past decade.  Some of 
that attention has been focused on the occurrence and prevention of harm from Adverse 
Drug Events (ADEs).  Between 19 and 61 percent of ADEs are preventable.  In order to 
prevent ADEs, they must first be detected.  Several methods have been used to detect 
ADEs, including voluntary reporting, intensified surveillance, and computerized 
monitoring.  Computerized monitoring has been shown to be complimentary to other 
methods in detecting ADEs.  However, very little research has been completed on this 
method in pediatrics. 
Pediatric patients pose unique challenges and risks because of physiological 
immaturity, lack of testing and information on medications, availability of appropriate 
medication formulations and strengths, and incomplete cognitive and communication 
development. 
This study examined the modification and implementation of an adult 
computerized ADE monitoring tool at one pediatric medical center.  It was implemented 
into the daily practice of pharmacy operations without increasing the pharmacy resources.  
Pharmacists printed daily reports containing alerts of possible ADEs.  They investigated 
each of the alerts and noted whether an ADE occurred and how much time was needed to 
investigate.  The main objective of this study was to increase the detection of ADEs in 




Over the 12-week study, 181 ADEs were identified via the computerized 
monitoring tool.  An additional 88 ADEs were voluntarily reported.  Overall, this 
represented a rate of 6.6 ADEs per 100 admissions and 14.8 ADEs per 1,000 patient 
days.  This result represented a significant increase in the detection of ADEs (p<0.0001) 
as compared to the same timeframe from the previous year.  The computerized 
monitoring tool had a positive predictive value (PPV) of 4.8 percent.  It took an average 
of 6.1 minutes to investigate alerts associated with an ADE, which was significantly 
higher than the time it took to investigate alerts not associated with an ADE (p<0.0001).  
Of the ADEs found with this tool, 10.5 percent were considered preventable. 
The use of a modified computerized ADE monitoring tool in the pediatric 
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Patients expect to receive care from highly trained and proficient medical 
professionals who will use the best practices known to modern medicine for their 
treatment.  In most cases these expectations are met.  However, even at the best of times, 
well laid plans do not always go as expected and mistakes are made.  When this occurs 
and an injury to the patient can result, it is said to be an adverse event.  At times there is 
nothing anyone could have done to predict or prevent an adverse event from occurring.  
For the remaining times, the adverse event is considered to be the result of medical error. 
The topic of patient safety picked up momentum in 1991 with the publication of 
the results of the Harvard Medical Practice Study.  That study reported that 3.7 percent of 
all hospitalized patients experienced an adverse event.1,2 While patient safety has always 
been considered critical, it received an unprecedented amount of attention when, in 1999, 
the Institute of Medicine (IOM) published its report “To Err is Human”.3  That report, 
based on two previous studies,1,4 estimated that between 44,000 and 98,000 people die 
each year in the United States from adverse events that are the result of medical error.  
There has been some debate whether these numbers are an accurate reflection of the true 
problem.5-7  Whether the actual number is higher or lower than reported is not necessarily 






The Harvard Medical Practice study further reported that complications related to 
medications were the most common type of adverse event and represented 19.4 percent 
of all adverse events in their study.2  This particular type of event has come to be known 
as an adverse drug event (ADE).  The definition from the Institute of Medicine, 
recommended by Nebeker et al.,8 and used in this study is “an injury resulting from 
medical intervention related to a drug.”3 
Pediatric patients are a particularly vulnerable population and have a greater 
potential to experience an ADE.  There is evidence that the occurrence of errors that 
could have potentially been an ADE occur at a rate three times higher in pediatric 
patients,9 even though incident rates have been shown to be approximately the same in 
pediatrics and adults.10 
 
Differences in Pediatrics 
Pediatric patients are a unique population with a distinct set of challenges 
unmatched by the adult population. 
 
Off-Label Medication Use 
The majority of medications that are used in pediatrics are used in a manner that 
is referred to as “off-label.”11-13  This means that the medication has been approved by the 
US Food and Drug Administration (FDA) for use in adults, but has not been adequately 
tested or labeled for treating children.  There are three main reasons behind this lack of 
testing in children.14-18  The first is that the medication market is smaller in children.  A 
smaller market means that the monetary benefit a pharmaceutical company may see from 





approved for children.  Therefore, their priority for pursing FDA approval for these 
medications would be greatly reduced.  The second reason is the technical difficulties in 
carrying out pediatric studies for FDA approval.  It is often difficult to enroll adequate 
numbers of children into a drug study because of the relatively small number of children 
are affected by many pediatric diseases.  This lack of patients may require a study to have 
multiple study sites in order to enroll a sufficient number of subjects, again increasing the 
cost of testing.  The inherent differences among age groups may also require a separate 
randomized control study for different age groups, such as infants, children, and 
adolescents.  There are also issues surrounding the possible need for multiple 
formulations of the medication, performing testing on smaller volume blood samples, 
along with providing appropriate pediatric environments, techniques, and equipment.  
These technical issues lead to a higher cost of testing.  The third reason for lack of testing 
in children is the complexity of ethical issues.  Children are unable to give “consent” 
because of their inability to fully understand the risks.  Therefore, a child’s parents take 
on this role of giving consent and enrolling them into a study.  However, even if a child’s 
parents enroll them, children age seven or older have the right to assent or dissent to 
being involved.  For example, a child may be enrolled in a study by their parents, but the 
child will dissent because one of the requirements is to obtain a blood sample and the 
child does not want to have a venipuncture to obtain the sample.  In addition, medical 
ethics committees are hesitant to allow drug trials in children, generally viewing them as 
a vulnerable population needing additional protections. 
Physicians can still prescribe these medications for pediatric patients, but without 





providers (LIP) which include physicians, nurse practitioners, and physician assistants, 
have inadequate information to make informed decisions about the benefits and risks of 
prescribing medications that may be advantageous in treating a child suffering from a 
particular disease or illness. 
Even though the majority of medications are used in an “off label” manner, 
improvement is being seen in the number of medications that are being tested and labeled 
for pediatric use.  This improvement is the result of the Best Pharmaceuticals for 
Children Act of 2002 (BPCA) and the Pediatric Research Equity Act of 2003 
(PREA).19,20  Both of these acts were reauthorized under the Food and Drug 
Administration Amendments Act of 2007 (FDAAA).21  These two pieces of legislation 
provide incentives and requirements for drug companies in regards to testing medications 
for use in pediatric patients. 
 
Physiological Differences 
Medications cannot just be reduced in dosage based on the patient’s size in 
relation to an adult.  There is a great deal of difference among pediatric patients in the 
maturation of their physiological systems (especially hepatic and renal).  These 
differences affect the pharmacokinetics of medications, that is how medications are 
absorbed, distributed, metabolized, and then excreted from the body.  These differences 
are most significant in neonates and young infants during their first year of life.11,13,18,22,23  
Good examples of the differences in dosing among different pediatric populations as a 
result of differing physiologic maturation are seen in the medications Phenytoin, used to 












Neonates Infants and Children Adults 
Phenytoin Loading Dose:  15-20 mg/kg 
in a single or divided dose 
 
Maintenance dose:   
Initial:  5 mg/kg/day in 2 
divided doses;  
Usual: 5-8 mg/kg/day in 2 
divided doses; some patients 
may require dosing every 8 
hours 
Loading Dose:  15-18 mg/kg 
in a single or divided dose 
 
Maintenance dose:   
Initial: 5 mg/kg/day in 2-3 
divided doses;  
Usual doses:   
0.5-3 years: 8-10 mg/kg/day  
4-6 years: 7.5-9 mg/kg/day  
7-9 years: 7-8 mg/kg/day  
10-16 years: 6-7 mg/kg/day  
 
Some patients require every 
8 hours dosing due to fast 
apparent half-life 
Loading Dose:  15-18 mg/kg in a 
single or divided dose 
 
Maintenance dose:   
Usual: 300 mg/day or 4-6 mg/kg/day 





Premature neonate,  
<1000 g: 3.5 mg/kg/dose 
every 24 hours  
 
0-4 weeks, <1200 g: 2.5 
mg/kg/dose every 18-24 
hours  
 
Postnatal age ≤7 days: 2.5 
mg/kg/dose every 12 hours  
 
Postnatal age >7 days:  
1200-2000 g: 2.5 mg/kg/dose 
every 8-12 hours  
>2000 g: 2.5 mg/kg/dose 
every 8 hours  
 
Once daily dosing:  
 
Premature neonates with 
normal renal function: 3.5-4 
mg/kg/dose every 24 hours  
 
Term neonates with normal 
renal function: 3.5-5 
mg/kg/dose every 24 hours  
 
 
<5 years: I.M., I.V.: 2.5 
mg/kg/dose every 8 hours*  
 
Once daily dosing in patients 
with normal renal function: 5-
7.5 mg/kg/dose every 24 
hours  
 
Children ≥5 years: I.M., I.V.: 
2-2.5 mg/kg/dose every 8 
hours*  
 
Once daily dosing in children 
with normal renal function: 5-




3-6 mg/kg/day in divided doses 
every 8 hours; studies of once daily 
dosing have used I.V. doses of 4-
6.6 mg/kg once daily 






At times the lack of pediatric medication information combined with 
physiological differences has had serious and tragic results.  One of the most tragic was 
the death of several newborns in the 1960s from the antibiotic chloramphenicol because 
their immature livers of the newborns were unable to break down and then excrete the 
medication.12,16  As a result of similar potential dangers, LIP’s may be hesitant to 
prescribe a medication out of fear of causing more harm than good. 
In addition, infants and children, especially critically ill children, are at greater 
risk to suffer increased harm from an ADE that is the result of an overdose.  This is 
because they have limited physiologic reserves with which to buffer the effects of this 
type of error.25-27 
 
Pediatric Formulation and Dosage Availability 
Since there are so few medications labeled for pediatric use, most medications are 
only available in adult dosages and formulations.  As a result, potential for error is 
introduced as available forms of the medications must be split into smaller doses, 
extemporaneously compounded into an appropriate liquid formulation, or otherwise 
mixed or diluted at the time of use.9,11,25-28  In some cases, the best option is to give 
injectable formulations orally.11 
Medication formulations based on adult needs are difficult if not impossible to 
measure for neonatal patients. Even a small measuring error can result in a significant 






Weight Based Dosing 
Almost all medications used in pediatrics are dosed according to the patient’s 
weight.  Once an LIP has the recommended dosing regimen, they still have to calculate 
the correct dose using a formula like mg/kg/dose up to an amount that in most cases is 
not to exceed the normal or maximum adult dosage.  Complicating the matter further, a 
child’s weight, especially neonates and infants, changes rapidly and may require 
recalculation of the proper dose for adequate therapeutic dosing during an inpatient 
stay.25  Calculating and/or recalculating dosage adds complexity to medication orders and 
introduces opportunity for errors resulting in therapeutic under or over dosing of the 
medication.  These errors can include misplacement of decimals, resulting in 10- or even 
100-fold overdoses or under-doses.11,25,26,28 
 
Cognitive and Communication Development 
Depending on a child’s level of cognitive development compared to an adult’s, 
they may be unable to recognize and then communicate that they are being given the 
wrong dose or the wrong medication.  In addition, depending on their communication 
development, they may be unable to communicate when they are experiencing the 
symptoms or effects of an ADE.9,26-28 
 
Methods of ADE Detection 
There are three common methods that have been employed to detect and monitor 
the occurrence of an ADE.  They include voluntary or spontaneous reporting, intensified 







Voluntary or spontaneous reporting is a method of reporting an ADE that has 
already been detected.  When an ADE is detected by a clinician, that clinician using this 
method would generally report it to the hospital by filling out a paper form or possibly an 
electronic form and submit it to the designated hospital department that then investigates 
the ADE further.  This type of reporting method is inexpensive and easy to implement as 
compared to the other methods that will be discussed later.  As a result, it has been the 
most common method used to monitor for the incidence of ADEs.  This method, though 
beneficial, has been known to underreport ADEs.29-33  Its effectiveness has even been 
described as “dismal at best.”34  A survey of physicians and nurses conducted by Taylor 
et al. in 2004 gave several reasons why underreporting of medication errors and events 
occur using this method.  The top four reasons were: one, the reporting individual being 
unsure about what is considered a medical error, two, the reporting individual being 
concerned about implicating others, three, the reporting individual being unsure about 
whose responsibility it is to report errors, and four, the idea that it is not important to 
report errors that did not reach the patient.32  The rate of detection in adults using 
voluntary reporting was reported by Jha et al. to be just 0.7 ADEs per 1,000 patient 
days.35  Another study completed in the pediatric population reported an incident rate of 
1.9 ADEs per 100 admissions and 1.8 ADEs per 1,000 patient days.36 
 
Intensified Surveillance 
Intensified surveillance including manual chart review has been shown to be 
effective at detecting ADEs and has been considered the gold standard for measuring the 





cost.34,35,37,38  There is also some evidence that it does not capture the entire range of 
ADEs.35  The detection rate of ADEs using this method among adult patients has been 
reported as 6.5 (adjusted) per 100 patient admissions37 and between 11.5 and 13.3 ADEs 
(adjusted) per 1,000 patient days.35,37  Among pediatric patients, intensified surveillance 
has reported ADE detection rates between 2.3 and 11.1 per 100 patient admissions and 
between 6.6 and 15.7 per 1,000 patient days.9,10,39  The Harvard Medical Practice Study 
reported Drug-related Adverse Events for patients less than 15 years old at a rate of 2.36 
per 1,000 discharges.2 
 
Computerized Surveillance 
Computerized surveillance has been reported to be, not only complementary to 
the previously mentioned methods, but also less expensive than intensified 
surveillance.34,35  While there are many examples of computerized monitoring being used 
to detect ADEs in the adult population,34,35,38 it is only now beginning to be explored and 
implemented in the pediatric population.36,40  Studies using computerized surveillance in 
adults have shown ADE rates between two and 6.2 ADEs per 100 patient 
admissions,34,35,41-43 with only the study from Jha et al. reporting 9.6 ADEs per 1,000 
patient days.35  Pediatric studies have shown ADE rates to be between 1.8 and 2.3 ADEs 
per 100 admissions and between 1.6 and 6.6 ADEs per 1,000 patient days.36,40 
 
Complementary Methods 
Surprisingly, when the ADEs detected using voluntary reporting and intensified 
surveillance are compared to those found using computerized ADE monitoring, there is 





adults reviewed all three methods together and found an adjusted ADE rate of 21 per 
1,000 inpatient days with only 12 percent or 76 of 617 ADEs being detected by both 
computerized and intensified surveillance.  In addition, there was only 0.5 percent or 
three of 617 ADEs that were found to be overlapping when comparing voluntary 
reporting and computerized surveillance.35  However, a study by Kilbridge et al.43 did 
identify that 59 percent or 42 of the 71 voluntarily reported ADEs were also detected by 
their computerized surveillance system.  They suspect that many of these were the result 
of pharmacists learning of ADEs from triggers and reporting them separately through the 
voluntary system.  In pediatric patients, Ferranti et al. found that only 4.3 percent or four 
of 78 ADEs overlapped between their computerized detection system and their voluntary 
reporting system.36  Kilbridge et al. found only three of the 160 ADEs, which represents 
1.9 percent of ADEs, were reported by both voluntary and computerized surveillance.40  
In addition, one study by Takata et al.39 used a manual trigger tool via chart review.  
These manual triggers were a set of 15 criteria that the person doing the chart review 
chart review looked for.  If they found an item in the chart that met the criteria this 
triggered or prompted them to review the chart in more depth for an associated ADE.  
They only had four ADEs reported via voluntary reporting during their study period.  All 
four of those ADEs were also detected by their manual trigger tool and represented 3.7 
percent of their 89 ADEs found via their tool. 
 
Preventability of ADEs 
From the reviewed studies if an ADE was determined to be preventable, it 





could have prevented the ADE from occurring.  The percentage of ADEs that have been 
found to be preventable in the adult population ranged from 20 to 50 percent.35,37,41,44,45   
The Adverse Drug Event Prevention Study Group, a consortium of individual 
researchers mostly from three instituations: the Brigham and Women’s Hospital, Harvard 
University, and the Massachusetts General Hospital found that 28 percent of ADEs in 
their study were preventable.  They also identified in two different articles37,45 the stage 
where the error occurred in the process known as the drug ordering and delivery process 
(Table 2).  This process describes the discrete steps used to get the medication to the 
patient after it has been prescribed.  It has several stages: prescribing, order processing, 
order review, dispensing, administration, and monitoring.  The Adverse Drug Event 
Prevention Study Group reported that errors occurred most often in physician ordering, 
followed by nurse administration, pharmacy dispensing, and then transcription and 
verification.37,45   
In pediatrics, the preventable ADEs ranged from 19 percent to 61 percent.9,10,39   
 
Table 2 
Drug ordering and delivery process 
 
Stage Description 
Prescribing In this stage the provider determines a need for a medication and then prescribes the 
medication for the patient. 
Order Processing Generally done by the unit clerk who “takes off” the order and sends it to pharmacy.  At Primary 
Children’s this is completed by faxing the order into the POMS system previously described. 
Order Review An RN reviews the order medication orders for inclusion of proper components, proper dosage, 
any allergies to the medication, etc and then notes that review on the order.  The nurse then 
transcribes the order to a medication administration record if still using a paper form to 
document medication administration; if they are documenting using the HELP system they 
would verify the order prior to administration.  Also during the order review step a pharmacist 
separately reviews the incoming order for inclusion of proper components, proper dosage, 
allergies, etc. 
Dispensing Once satisfied with the order the pharmacist then dispenses the medication. 
Administration The nurse administers the medication as per the written order. 






The pediatric study by Takata et al. described that the most common error occurred in the 
monitoring stage followed by prescribing and dispensing.  It is interesting to note that 
neither of the previous pediatric studies evaluating computerized surveillance determined 
the number of preventable ADEs found via computerized monitoring. 
 
Impact of ADE 
Two adult population studies looked at the impact that an ADE had on the length 
of stay (LOS) and on the cost of hospitalization for patients.  The first study by Classen et 
al. was conducted at Intermountain’s LDS Hospital on data from January 1, 1990 to 
December 31, 1993.  It found that ADEs had an attributable increase in patient LOS of 
1.74 days at a cost of $2,013 per admission.41  The second study by Bates et al. was 
conducted at the Brigham and Women’s and Massachusetts General Hospitals on data 
from February 1993 to July 1993.  That study found an increased LOS of 2.2 days with 
an increased cost of $2,595.  This same study also found that if the ADE was preventable 
the cost increased to $4,685.46 
 
Hypothesis and Objectives 
The hypothesis for the study reported here is that a modified adult computerized 
ADE trigger tool will increase the detection of ADEs in a Pediatric population when 
compared to the current voluntary reporting method.  To accept or reject this hypothesis 
we conducted a study of the implementation of a modified adult tool in the pediatric 






The objectives of this study were as follows: 
1. Modify existing triggers where necessary to better represent the differences in 
pediatric patients. 
2. Add new triggers that have a potential to increase the detection of additional 
ADEs in the pediatric setting. 
3. Implement the updated ADE alerting tool in a pediatric population. 
4. Compare the detection rate of the computerized ADE tool at Primary 
Children’s Medical Center to the current method of voluntary reporting. 
5. Evaluate the effectiveness of the computerized surveillance ADE triggers in a 
pediatric setting. 
6. Evaluate preventable ADEs found via the computerized ADE detection tool 
and compare them against the preventable ADEs found via voluntary 
reporting. 
7. Evaluate the amount of time it takes to investigate non-ADE alerts versus 









At the time of this study Primary Children’s Medical Center, located in Salt Lake 
City, Utah, was a 252-bed, tertiary care pediatric medical center providing care for five 
states in the Intermountain West (Utah, Idaho, Montana, Nevada, and Wyoming) and 
primary pediatric care in Utah.  It is owned and operated by Intermountain Healthcare, a 
nonprofit community owned system of hospitals, surgery centers, doctors, clinics, 
homecare, and hospice providers.  Primary Children’s Medical Center is also affiliated 
with the University of Utah School of Medicine and is its primary pediatric training site.  
This study was approved by the Institutional Review Boards (IRB) of the University of 
Utah and Intermountain Healthcare. 
 
Patient Population 
Study patients included all patients admitted to an inpatient bed in one of eight 
inpatient units during a 12-week period of time (84 days) from February 2, 2009 through 
April 26, 2009.  The inpatient units included the Children’s Medical Unit (CMU), 
Children’s Surgical Unit (CSU), Immunocompromised Unit (ICS), Infant Medical 
Surgical Unit (IMSU), Newborn Intensive Care Unit (NICU), Neuroscience Trauma Unit 
(NTU), Pediatric Intensive Care Unit (PICU), and inpatients admitted to the Rapid 
Treatment Unit (RTU).  The only inpatient unit not included was the Psychiatric Unit.  It 





primary campus and the processes necessary to include them in the study were 
considered impractical. 
 
ADE Prevention Methods Already in Place 
Licensed Independent Practitioner (LIP) orders were handwritten on order sheets 
with a few exceptions where a paper ordering template was used.  Although orders were 
still handwritten, the facility had several methods for preventing ADEs already in place.  
The prevention methods included, but were not limited to, the Pharmacy Order 
Management System (POMS).  Handwritten orders were scanned into POMS by the unit 
clerk on each unit.  Once an order was scanned, it was transmitted to Pharmacy staff.  
The pharmacy staff was then able to review and track each incoming order.  They were 
also able to tag individual orders that required follow-up with the ordering LIP.  Once all 
tagged issues were resolved, the Pharmacy staff then hand entered each medication 
related order into the Pharmacy subsystem of the hospital’s electronic medical record 
(EMR).  The EMR in place at the facility was the Health Evaluation through Logical 
Processing (HELP) system.47  This system was first developed under the direction of 
Homer R. Warner and has been in use for more than 35 years at Intermountain’s LDS 
Hospital and for more than 15 years at Primary Children’s Medical Center.48  When 
orders were entered into the Pharmacy subsystem, the system checked them for allergies, 
high and low dose parameters, and drug-drug interactions.  If an allergy, out of range 
order, or drug-drug interaction was found, an on-screen alert was generated.   
Barcode Medication Administration (BCMA) was in place on five of the eight 
inpatient units included in the study.  The three units not using BCMA, instead, used a 





HELP Pharmacy subsystem.  A McKesson medication dispensing robot was used to 
dispense standardized doses of medications and was responsible for dispensing 
approximately 40 percent of all medications to patients.  Acudose dispensing cabinets 
were available on each of the inpatient units.  A separate total parenteral nutrition (TPN) 
compounder, also in the pharmacy, was responsible for preparing and dispensing all of 
the TPN solutions used in the hospital.  In addition to the above, pharmacists actively 
participated in multidisciplinary rounds. 
 
Intervention 
The computerized ADE monitoring tool that was the basis for this study was first 
developed at Intermountain’s LDS Hospital and information regarding its effectiveness 
has been previously published.34,49,50  Since first being described and implemented, the 
monitoring tool has had periodic modifications and enhancements and has subsequently 
been implemented extensively throughout Intermountain Healthcare hospitals. 
 
Computerized ADE Monitoring Tool Basics 
The monitoring tool was programmed with rules that contained specific criteria.  
When the criteria were met, the tool generated a notification that was included in a paper 
report.  The term “trigger” was used to describe the rules of the tool, and the term “alert” 
was used to denote the notifications of possible ADEs generated by the rule or trigger 
that needed to be investigated and confirmed or ruled out as an actual ADE.  A 
designated pharmacist received notification of the alerts by printing the Possible Adverse 
Drug Event Report.  The pharmacist would then investigate the alert to determine if an 






Prior to the beginning of this study, the ADE monitoring tool used in adults had 
87 active triggers.  Two of the trigger categories (Pharmacist and Nursing) were part of 
an enhanced voluntary reporting tool where suspected ADEs could be reported via this 
tool by pharmacy and nursing personnel for further investigation.  Other categories of 
triggers included medication orders, laboratory results, including serum drug levels, and 
physiologic monitoring triggers. 
Before being placed into service each trigger was reviewed by a team of pediatric 
pharmacists for relevance to the study location and population.  Based on the review and 
recommendation of the pharmacist team, 14 triggers were modified, 11 new triggers were 
added, and 16 triggers were not implemented (Table 3).  Of those triggers not 
implemented, 15 were part of the enhanced voluntary reporting tool and were not 
consistent with the processes already in place at the facility for nursing and pharmacy 
reporting of potential ADEs.  For the 58 triggers that were implemented unchanged, some 
of those triggers were determined to be appropriate as written (for example potassium 
level, carbamazepine level and digoxin level), while other triggers were determined to be 
of little or no benefit to pediatrics and yet would be harmless if implemented without any 
changes (for example, opium and paregoric). 
Some of the original triggers had rules to exclude patients with certain 
preliminary coded admission diagnoses.  These coded diagnoses were entered into the 
adult patient’s record shortly after the patient’s admission.  At Primary Children’s, the 
diagnostic codes are not entered until after the patient has been discharged.  Therefore, 








Triggers added, modified, or removed from monitoring tool 
 
Action Trigger Detail 
Modified Heart rate less than 45 Included age specific values 
 Respiratory rate less than 8  Included age specific values 
 Prednisone dose greater than or equal to 
50 mg 
Excluded certain free text diagnoses related to asthma, 
bronchiolitis, and other respiratory diagnoses. 
 Phenytoin ordered Included administration of Fosphenytoin. 
 Phenobarbital ordered  Excluded certain free text diagnoses related to seizure 
diagnosis and brain injuries. 
 Vitamin K ordered and age greater than 
or equal to 1years old 
Age changed to be greater than 30 days. 
 Platelets less than or equal to 50  Turned off for ICS unit due to expected high false negative 
values 
 WBC less than or equal to 2.5  Turned off for ICS unit due to expected high false negative 
values 
 Valproic acid greater than 100  Changed to greater than 125 
 Cyclosporin greater than100  Changed to greater than 500 
 Vanco P greater than 40  Changed to greater than 50 
 Gent P greater than 10  Changed to greater than 12 
 Tobra P greater than 10  Excluded free-text diagnoses related to Cystic Fibrosis 
 Tobra T greater than 2 Excluded free-text diagnoses related to Cystic Fibrosis 
Added Phentolamine Phentolamine ordered 
 Hydrochloric acid Hydrocholoric acid ordered 
 Racemic Epinephrine ordered Racemic Epinephrine ordered 
 Viokase 8 and Sodium Bicarbonate tablet Viokase 8 and Sodium Bicarbonate tablet ordered 
 Wydase Wydase ordered 
 Nubain Nubain ordered <= 0.03 mg/kg/dose 
 Acetylcysteine Acetlycysteine ordered 
 Tacrolimus level Tacrolimus, greater than15 
 Caffeine level Any Caffeine level 
 Anti-factor Xa Anti-factor Xa greater than1 
 EOS EOS greater than or equal to 7 
Removed Abrupt stop order  
 Abrupt reduction of drug   
 Anaphylaxis  
 Mental change  
 Diarrhea  
 Fever  
 Respiratory change  
 Rash/hives/itching  
 Seizure  
 Hearing change  
 Heart Rate Change  
 Other  
 Hypertension  
 Hypotension  
 Incident report  






false positive rate would be higher and the Positive Predictive Value (PPV) would be 
lower for those triggers that relied on excluding certain diagnostic codes than in the adult 
facilities.  In cases where the false positive rate was anticipated to be especially high, the 
free-text diagnoses that most closely matched the coded diagnoses were excluded from 
the trigger.  Those triggers that were affected by not having coded diagnoses or where 
free text diagnosis exclusion was included were considered to not be modified. 
After the modifications were completed there were 83 active triggers that were 
implemented (see Table 4). 
 
Alert Generation 
The information used to determine if trigger criteria were met and an alert should 
be generated came from different sources.  Laboratory information was stored in HELP 
but originally received via an HL7 interface from the Sunquest laboratory information 
system.  Physiological data was also stored in HELP and received via a direct RS237 
connection from the Phillip’s monitors.  The rest of the information was generated inside 
of the HELP system via the pharmacy and nursing subsystems.  When information that 
was used as a trigger was saved in the HELP system, it was exposed to the rules engine, 
which reviewed the data for the specified criteria in the triggers.  If the criteria were met 
an alert was generated. 
When the pharmacist logged into the computerized ADE Monitor on HELP, a 
menu was presented that had options to print the Possible Adverse Drug Event (Figure 1).  
Each menu option was specific to a particular pharmacy team and printed only the 







Triggers implemented at PCMC 
 
Type of Trigger Trigger Trigger Rule Detail 
Lab Alerts & drug levels SGOT SGOT >= 150 
 SGPT SGPT >= 150  
 Billirubin Billirubin >= 10 
 EOS EOS >= 7 
 Platelet count Platelet Count <= 50 - Turned off on ICS due to 
anticipated high false positive rate 
 WBC WBC <= 2.5 - Turned off on ICS due to anticipated high 
false positive rate 
 Carbamazepime carbamazepine > 10 
 Digitoxin digitoxin > 30 
 Digoxin digoxin > 2 
 Disopypamide disopypamide > 5 
 Ethosuximide ethosuximide > 100 
 Lidocaine lidocaine > 5 
 NAPA NAPA > 20 
 Procainamide Procainamide > 10 
 Phenobarbital Phenobarbital > 45 
 Phenytoin Phenytoin > 20 
 Quinidine Quinidine > 5 
 Theophylline Theophylline > 20 
 Valporic Acid Valproic Acid > 125 
 Cyclosporin Cyclosporin > 500 
 Vanco peak Vancomycin Peak > 50 
 Vanco trough Vanco Trough > 20 
 Gent peak Gentamycin Peak > 12 
 Gent trough Gentamycin Trough > 2 
 Tobra peak Tobramycin Peak > 10 excluded are free-text diagnosis 
related to Cystic Fibrosis 
 Tobra trough Tobramycin Trough > 2 
 Amikacin peak Amikacin Peak > 30 
 Amikacin trough Amikacin Trough > 10 
 C. difficile C. difficile 
 Doubling of Cr Doubling of Creatinine 
 Glucose Glucose < 50 
 Glucose Glucose > 350 
 Potassium Potassium < 3.0 and decrease of .8 or < 2.6 and 
decrease of .5 within 72hrs and on K altering drug 
 INR INR > 3.0  (INR increase by 0.3 w/I 24hr or increase by 
0.5 w/I 48hr and active warfarin order 
 PTT PTT > 100 ( 2 or more PTTs > 100 within 36hrs) 
 Tacrolimus Tacrolimus > 15 
 Caffeine level Caffeine level ordered 
 Anti-factor Xa Anti-factor Xa > 1 
Pharmacy Orders Diphenhydramine Benadryl ordered but not ALG, OKT3, ampho, Cancer 
drug, cardiac drug within 3 hrs, Reopro, or HGB drop >= 
3 
 Steroid cream Steroids ordered except (azmacort, nasalide, aerobid) 
and not QHS 
 Epinephrine Epinephrine ordered 





Table 4 (Continued)   
Type of Trigger Trigger Trigger Rule Detail 
 Phenytoin Phenytoin ordered, exclude free-text diagnosis related to 
seizure disorder, brain tumor, stroke, or traumatic brain 
injury. 
 Phenobarbital Phenobarbital ordered, exclude free-text diagnosis 
related to seizure disorder, brain tumor, stroke, or 
traumatic brain injury. 
 Prednisone Prednisone ordered >=50 mg, exclude free-text 
diagnosis related to asthma, reactive airway disease 
(RAD), RSV, bronchiolitis, or croup 
 Caladryl Caladryl ordered 
 Calamine Calamine ordered 
 Kayexalate Kayexalate ordered 
 Vitamin K Vitamin K ordered but age >= 30 days and not on TPN 
 Digibind Digibind ordered 
 Activated charcoal Activated charcoal ordered 
 Donnagel Donnagel ordered 
 Kaopectate Kaopectate ordered 
 Lomotil Lomotil ordered 
 Opium Opium ordered 
 Paregoric Paregoric ordered 
 Loperamide Loperaminde ordered 
 Atropine Atropine ordered 
 Benztropine Benztropine ordered 
 Inapsine Inapsine ordered 
 Protamine Protamine ordered 
 Flumazenil Flumazenil ordered 
 Haloperidol Haloperidol ordered 
 Solumedrol Solumedrol ordered 
 Alteplase Altiplace ordered 
 Argatroban Agratroban ordered 
 Lepirudin Lepirudin ordered 
 Phentolamine Phentolamine ordered 
 Hydrochloric acid Hydrochloric acid ordered 
 Racemic epinephrine Racemic epinephrine ordered 
 Viokase and Sodium 
Bicarbonate tablet 
Viokase and Sodium Bicarbonate tablet ordered 
 Wydase Wydase ordered 
 Nubain Nubain ordered <= 0.03 mg/kg/dose 
 Acetylcysteine Acetylcysteine ordered 
 Neostigmine Neostigmine ordered 
 Hydrocortisone IV Hydrocortisone IV ordered 
Physiology Heart rate Age > 10y: HR < 45 or > 120 
   Age > 5y and < 10y: HR < 50 or > 160 
   Age > 3y and < 5y: HR < 50 or > 160 
   Age > 12m and < 3y: HR < 50 or > 160 
   Age > 1m and < 12m: HR < 60 or > 205 
   Age < 1m: HR < 60 or > 220 
 Respiratory rate Age > 10y: HR < 8 or > 25 
   Age > 5y and < 10y: HR < 12 or > 30 
   Age > 3y and < 5y: HR < 15 or > 50 
   Age > 12m and < 3y: HR < 15 or > 55 
   Age > 1m and < 12m: HR < 20 or > 80 





   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Table 4 (Continued)   
Type of Trigger Trigger Trigger Rule Detail 
 SPO2 SPO2 < 80 % 
 blood pressure deviation 50% blood pressure deviation from baseline X 3 
 SBP < 100 SBP < 100 (decrease by 20 w/I 48hrs and on 
hypotensive drug) 




Figure 1.  Menu options available to pharmacists in
monitor tool 
an option was selected the pharmacist was given the opportunity to enter 
in the past they wanted to retrieve alerts.
The ADE Monitor
unit and within the specified time range.  It then took the first alert that it found for the 
specific patient and organized th
the trigger name and its criteria), patient demographic data (encounter number, patient 
name, age, sex, room, medical record number, attending physician, admission date, and 
the free-text reason for admission), and current and discontinued medication information 
into one organized alert.  The alert was then included in the printed Possible Adverse 
Drug Event report.  The printed report only contain
if multiple alerts were generated
that only one alert was necessary because the pharmacist would then review the patient as 
a whole looking for any ADE that might have occurred.
 
Pharmacy Review of Alerts
The computerized monitoring tool was implemented directly into the pharmacist’s 
normal daily workflow without increasing pharmacy staffing or other resources to 
investigate the alerts. 
 
 
 the computerized 
 
 
 looked for any alerts that had been generated on the specified 
e alert information (date and time of the 
ed one alert per patient per day, even 








how many days 






Figure 2.  Example of printed alert from the potential adverse drug event report 
 
Pharmacists were trained on how and when to run the report from the 
computerized ADE monitoring tool, as well as what content would be available in the 
report.  They were instructed to print the Possible Adverse Drug Event Report every 
morning Tuesday through Friday for the previous day.  Due to decreased staffing in 
Pharmacy on Saturday and Sunday, the report was not printed on those two days.  Instead 
it was printed on Monday for the previous three days, with the exception of President’s 
day (Monday February 16, 2009) when the report was printed on Tuesday for the 
previous four days.  The ICS unit Pharmacy staff, whose staffing patterns were different 
than the rest of the hospital chose to run the report every day for the previous day.  Once 
the report was printed, the unit pharmacists were had been instructed to investigate each 





report from nursing staff or other clinicians.  The pharmacy staff was instructed to the 
IOM definition of an ADE, what constituted an ADE, and were to note on the report 
whether an alert was associated with an ADE or not.  If the alert was associated with an 
ADE, they were asked to report it to the hospital in the same manner that they would 
normally report an ADE that was discovered via another method.  The normal method of 
reporting an ADE involved entering the details of the ADE into the voluntary, web-based 
reporting tool called Web Event.  In addition to reporting ADEs, the pharmacist was also 
asked to note on the paper report the amount of time it took to investigate each alert.  The 
minimum time for investigating an alert was set at one minute. 
Once the ADE was entered into the Web Event system it was further reviewed by 
either a Risk Management staff member or by the Pharmacy Clinical Specialist and 
entered into another tool call Medication Event Verification (MEV) were it was assigned 
a severity of harm category.  Each ADE discovered using the computerized monitoring 
tool was reviewed again by the Pharmacy Clinical Specialist to confirm that an ADE did 
occur.  The Pharmacy Clinical Specialist also assigned the severity of harm category or 
confirmed the category that had been assigned by Risk Management.  ADEs that 
occurred prior to admission or that were the result of an intentional overdose on the part 
of the patient were not included in the study.   
The severity of harm incurred as a result of the ADE was determined using the 
National Coordinating Council for Medication Error Reporting and Prevention (NCC 
MERP) Index for Categorizing Medication Errors (Table 5).51  Only categories “E” 







Index for categorizing medication errors 
 
Category Description 
A Circumstances or event that have the capacity to cause adverse event  
B An event occurred but did not reach the patient  
C An event occurred that reached the patient but did not cause harm  
D An event occurred that resulted in the need for increased patient monitoring but no patient harm  
E An event occurred that may have contributed to or resulted in temporary harm to the patient and 
required intervention  
F An event occurred that required treatment and a higher level of care such as initial or prolonged 
hospitalization and caused temporary or reversible effects to the patient.  
G An event occurred that resulted in permanent patient harm  
H An event occurred that resulted in near-death requiring intervention necessary to sustain life from 
which the patient recovered  
I An event occurred that resulted in patient death  
*Based on the NCC MERP Index for Categorizing Medication Errors 2001© 
 
severity until category “I”.  Category I was defined as death of the patient due in part or 
entirely to the ADE.  Therefore, only those events within these categories were deemed 
ADEs. 
If the ADE was determined to be preventable, the ADE or event was further 
categorized according to the stage in which the drug ordering and delivery process error 
occurred.  An error can be introduced at any one of the stages and may be perpetuated 
through to each phase if not discovered.  Therefore, errors or ADEs may have an error 
type that is counted in more than one stage of the process, so actual number of events will 







The statistical significance of the findings was measured using Chi-Square, 
Unpaired t-Test, and Fisher’s Exact Test as appropriate.  Calculations were performed 









During the 12 week study timeframe there were a total of 3,562 unique patients.  
Females represented 44.7 percent and males 55.3 percent.  The gender disparity seen is 
consistent with other studies.53-55  There were 4,104 encounters or admissions to an 
inpatient bed on one of the eight units previously described.  Females accounted for 44.4 
percent of admissions and males 55.6 percent (see Table 6).  The number of admissions 
per patient ranged from between one and eight, with 89.5 percent of the patients having 
only one admission and 97.2 percent of the patients having one or two admissions.  The 
admission rates for male and female patients were compared against data from 2008 and 
2007 and were found not to be statistically significant (p = 0.8).   
Patient age was defined as age upon admission to the hospital.  The average age 
of all admissions was 5.3 years, with a standard deviation of 5.9 years and a range of less 
than one day to 36.9 years (see Table 7).  The age of male admissions were compared 
against the female admissions and were not found to be statistically significant (p = 0.1). 
The number of patients greater than or equal to 18 years was 74 or 2.1 percent of 
 
Table 6 
Patients and admissions for study time frame and the previous two years 
 
Gender Study Patients (%) Study Admissions (%) Patients 2008 (%) Patients 2007 (%) 
Female 1,592 (44.7) 1,822 (44.4) 4,863 (45.3) 4,552 (45) 
Male 1,970 (55.3) 2282 (55.6) 5,870 (54.7) 5,565 (55) 






Patient age data upon admission 
 
Gender 
Study Patient Age 
(Std. Dev.) 
Age Range Study 
Patients 
2008 Patient Age Same 
Study Time frame (Std. Dev.) 
Age Range 2008 
Patients 
Female 5.5 (6.1) < 1 day to 36.9 years 5.4 (6.1) < 1 day to 43.6 years 
Male 5.2 (5.8) < 1 day to 27.7 years 5.2 (6) < 1 day to 56.7 years 
All Patients 5.3 (5.9) < 1 day to 36.9 years 5.3 (6.03) < 1 day to 56.7 years 
 
all patients and accounted for 122 encounters or three percent of all admissions and is 
similar to the study by Kaushal, et al.9  It is noteworthy to mention that one patient with 
multiple admissions turned 18 during the study time frame between admissions to the 
hospital and was thus counted in both categories. 
During the study timeframe, there were a total of 18,204 patient days (44 percent 
female, 56 percent male) with an average number of 5.1 study days per patient, a standard 
deviation of 8.5 days, and a range of 0.01 study days to 84 study days per patient (see 
Table 8).  The average number of study days for females was compared against that for 
males and was not found to be statistically significant (p = 0.12).  The low study day of 
0.01 was the result of the patient being admitted 15 minutes prior to the end of the study. 
 
ADEs 
Overall, during the study period there were a total of 269 confirmed ADEs from 
the computerized monitoring tool and voluntary reporting.  This total represented 6.6  
 
Table 8 
Description of patient study days 
 
 
Patient Days (%) Avg Study Days Std. Dev. Range 
Female 7,958 (44) 5 8.2 0.01 to 84 
Male 10,240 (56) 5.2 8.8 0.01 to 84 





ADEs per 100 admissions and 14.8 ADEs per 1,000 patient days.  Of the total ADEs, 181 
were associated with the computerized monitoring tool and the other 88 were voluntarily 
reported.  Of the 269 ADEs 83, or 31 percent were considered to be preventable.  
Nineteen of these were identified using the computerized ADE monitoring tool and 64 
were from voluntary reporting. 
 
ADEs by Nursing Unit 
The ADEs were further parsed by unit and are represented in Table 9.  The units 
with the highest number of ADEs per 100 admissions were the PICU, ICS, and NICU.  
These three units admit the highest acuity patients in the hospital and subsequently those 
patients receive the largest number of medications.  They are also the three units where 
BCMA was not used during this study. 
 
ADEs via Computerized Monitoring 
The 181 ADEs associated with the computerized monitoring tool occurred in 136 
unique patients over 140 admissions.  Each patient had between one and five ADEs with  
 
Table 9 











ADEs per 100 
admissions 
ADEs per 1000 
pt. days 
CMU 782 2441 16 14 30 3.8 12.3 
CSU 781 2577 19 11 30 3.8 11.6 
ICS 161 1753 18 4 22 13.7 12.5 
IMSU 1059 3654 4 9 13 1.2 3.6 
NICU 190 3200 10 14 24 12.6 7.5 
NTU 591 1852 16 16 32 5.4 17.3 
PICU 586 2404 98 20 118 20.1 49.1 






79.4 percent of patients having only one ADE and 85.3 percent of patients having one or 
two ADEs.  When normalized, these ADEs represented 4.4 ADEs per 100 admissions 
and 9.9 ADEs per 1,000 patient days.  There were 179 ADEs categorized with the 
severity of “E” and two were categorized as “F” on the NCC MERP severity scale. 
Nineteen or 10.5 percent of the ADEs were determined to be preventable.  Of the 
preventable ADEs, 15 had available information regarding where the error occurred in 
the medication ordering and delivery process.  The most common stage identified was 
administration, followed by prescribing, then dispensing and order review.  The most 
common error type was IV infiltration, followed by overdose, and under dose (see Table 
10). 
There were 56 different drugs in 19 therapeutic drug categories that were listed as 
being responsible for at least one ADE with the most common drug categories being 
diuretics, antibiotics, narcotic analgesics, intravenous nutritional therapy, and 
antineoplastic agents.  The most common drugs associated with ADEs were furosemide, 
vancomycin, bumetanide, morphine, and TPN (see Table 11). 
 
Table 10 








Dispensing Administration Monitoring Totals 
Overdose 4 0 2 2 4 0 12 
Underdose 0 0 0 0 1 0 1 
IV Infiltration 0 0 0 0 10 0 10 







Drug category and drugs involved in ADEs 
 
Drug Category Drug Name 
# of 
ADEs 
Diuretics Furosemide 52 
 Bumetanide 15 
 Chlorothiazide 1 
Antibiotics Vancomycin 17 
 Piperacillin-Tazobactam 5 
 Ceftriaxone 4 
 Gentamicin 4 
 Cefazolin 2 
 Ampicillin 2 
 Ceftazidime 1 
 Ciprofloxacin 1 
 Amoxicillin-Pot Clavulanate 1 
 Clindamycin HCl 1 
 Nafcillin 1 
 Metronidazole 1 
 Linezolid 1 
 Sulfamethoxazole 1 
 Meropenem 1 
Narcotic Analgesic Morphine 9 
 Fentanyl 5 
 Hydrocodone-Acetaminophen 3 
 Fentanyl-Bupivacaine in NS(PF) 2 
 Hydromorphone 2 
 Hydromorphone-Bupiv in NS (PF) 1 
 Oxycodone 1 
Intravenous Nutritional Therapy Amino Acids 4.25%-Lytes-Ca-D10 6 
 Amino Acids 4.25%-Lytes-Ca-D20 1 
 Amino Acids 4.5 %-Lytes-Ca-D25 1 
 Fat Emulsion 1 
Antineoplastic Agent Methotrexate 3 
 Cytarabine 2 
 Daunorubicin 1 
 Cisplatin 1 
 Pegaspargase 1 
Bronchodilator Albuterol 3 
 Albuterol Sulfate 1 
 Terbutaline 1 
Anticoagulant Enoxaparin 2 
 Heparin (Porcine) 1 
 Heparin (Porcine) in D5W 1 
Immunosuppressant Tacrolimus 3 
 Cyclosporine 1 
Corticosteroid Methylprednisolone 1 
 Prednisolone 1 
 Dexamethasone 1 
 Hydrocortisone 1 
Benzodiazepine Midazolam 1 
 Lorazepam 1 










































  Table 11 (Continued) 
  
Drug Category Drug Name 
# of 
ADEs 
Antiviral Valganciclovir 1 
ACE Inhibitor Enalapril Maleate 1 
Immune Globulin Lymphocyte,Anti-Thymo Imm Glob 1 
Antifungal Voriconazole 1 
Anticonvulsant Fosphenytoin 1 
Mineral Ferrous Sulfate 1 
Antiemetic Promethazine 1 
NSAID Ibuprofen 1 






Voluntarily Reported ADEs during Study 
In addition to the 181 ADEs that were identified with the computerized ADE 
monitoring tool, there were an additional 88 ADEs that were voluntarily reported via the 
hospital’s Web-Event system during the study period. 
Eighty seven of the voluntarily reported ADEs were categorized as “E” and one 
was categorized as “F” on the NCC MERP severity scale.  These additional ADEs 
occurred in 78 different patients, over 79 admissions.  These voluntarily reported ADEs 
represent 2.1 ADEs per 100 admissions and 4.8 ADEs per 1,000 patient days.  In 71 of 
these ADEs the associated drug was listed.  There were 39 different drugs involved in 18 
therapeutic categories (see Table 12).  The most common therapeutic categories were: 
antibiotics, intravenous fluid, intravenous nutritional therapy, narcotic analgesic, and 
anti-neoplastic. 
Sixty-four of the 88 ADEs or 72.7 percent of the ADEs were determined to be 
preventable.  Of the preventable ADEs, 62 had available information regarding where the 
error occurred in the medication management process.  The most common stage 
identified was administration, followed by dispensing, prescribing, order review, and 
order processing.  The most common error type was IV infiltration, followed by wrong 
drug, overdose, and drug not reordered (see Table 13). 
 
Computerized Monitoring and Voluntary Reporting Overlap 
We were not able to determine if there was any overlap between the ADEs 
identified by the Computerized Monitoring tool and those reported voluntarily because 
the computerized ADE monitoring tool was implemented to the same pharmacy staff that 






Drug categories for voluntarily reported study ADEs 
 
Drug Category Drug Name # of ADEs 
Antibiotics Vancomycin 10 
 Ampicillin 2 
 Cefotaxime 2 
 Amoxicillin 1 
 Amphotericin B 1 
 Cefazolin 1 
 Clindamycin HCl 1 
 Meropenem 1 
 Nafcillin 1 
 Rifampin 1 
Intravenous Fluid D5-1/2 NS & Potassium Chloride 6 
 D10-1/4NS & Potassium Chloride 2 
 Dextrose 10%-1/2 Normal Saline 2 
 Dextrose 5%-1/2 Normal Saline 1 
 Dextrose 5% in Water (D5W) 1 
 Dextrose 10% in Water (D10W) 1 
 Lactated Ringers 1 
Intravenous Nutritional Therapy Fat Emulsion 5 
 Amino Acids 4.25%-Lytes-Ca-D10 4 
Narcotic Analgesic Morphine 6 
 Fentanyl-Bupivacaine in NS(PF) 1 
 Hydrocodone-Acetaminophen 1 
Antineoplastic Agent Ifosfamide 3 
 Methotrexate 2 
Benzodiazepine Diazepam 1 
 Lorazepam 1 
Anesthetic, General Ketamine 1 
Anticoagulant Heparin (Porcine) 1 
Antidote, Benzodiazepine Flumazenil 1 
Antifungal Voriconazole 1 
Antihypertensive Nitroprusside 1 
Beta Blocker Esmolol 1 
Hypoglycemic Metformin 1 
Immune Globulin Immune Globulin (Human) (IGG) 1 
Insulin, Long-Acting Insulin Glargine 1 
Insulin, Rapid-Acting Insulin Aspart 1 
Mineral Calcium Gluconate 1 














Dispensing Administration Monitoring Totals 
Drug Not Reordered 0 0 0 0 1 0 1 
Overdose 1 0 0 2 3 0 6 
IV Infiltration 0 0 0 0 53 0 53 
Wrong Drug 2 1 2 2 4 0 11 
Totals 3 1 2 4 61 0 70 
 
overlap, we would have had to create and then implement the monitoring tool within a 
separate more limited team of pharmacy staff that investigated and tracked ADEs 
independently of the floor pharmacists.  However, all ADEs reported during the study 
timeframe were reviewed and ADEs identified via the monitoring tool were separated 
from those not related to the monitoring tool.  The 88 ADEs not associated with the 
computerized monitoring tool were the voluntarily reported ADEs which have been 
previously described. 
 
Voluntarily Reported ADEs in 2008 during same time period 
During the same time period in 2008, there were 96 ADEs reported in 87 patients 
over 87 admissions via the voluntary reporting system.  Of those, 95 were categorized as 
“E” and one was categorized as “F” on the NCC MERP severity scale.  Those ADEs 
represented 2.5 ADEs per 100 admissions and 5.3 ADEs per 1,000 patient days.  There 
were 69 ADEs where the implicated drug was listed; comprising 33 different drugs from 
16 therapeutic categories (see Table 14).  The most common therapeutic categories were: 







2008 voluntarily reported ADEs by drug category 
 
Drug Category Drug Name # of ADEs 
Antibiotics Vancomycin 9 
 Ampicillin 4 
 Cefotaxime 2 
 Clindamycin HCl 2 
 Cefazolin 1 
 Ceftriaxone 1 
 Cefuroxime Sodium 1 
 Doxycycline 1 
 Nafcillin 1 
Intravenous Fluid D5-1/2 NS & Potassium Chloride 6 
 Dextrose 5%-1/2 Normal Saline 3 
 Dextrose 10% in Water (D10W) 2 
 Dextrose 10%-1/4 Normal Saline 1 
 Dextrose 10%-Normal Saline 1 
Intravenous Nutrition Therapy Amino Acids 4.25%-Lytes-Ca-D10 11 
 Amino Acid Infusion 4.25%-D10W 1 
Narcotic Analgesic Morphine 4 
 Fentanyl  1 
 Hydrocodone-Acetaminophen 1 
Antihistamine Diphenhydramine 2 
 Cyproheptadine 1 
Antiarrhythmic Amiodarone 2 
Electrolyte Supplement Potassium Phosphate 1 
 Sodium Chloride 1 
Antineoplastic Agent Ifosfamide 1 
Adrenergic Agonist Agent Norepinephrine Bitartrate 1 
Anesthetic, General Pentobarbital 1 
Antiemetic Promethazine 1 
Antifungal Fluconazole 1 
Bronchodilator Albuterol 1 
Diuretic Furosemide 1 
Hyperglycemic Dextrose 1 






Eighty six or 89.6 percent of these 2008 ADEs were determined to be 
preventable.  Of the preventable ADEs, all 86 had available information regarding where 
the error occurred in the drug ordering and delivery process.  The most common stage 
identified was administration, followed by dispensing, then order review and prescribing.  
The most common error type was IV infiltration, followed by overdose, other, dose 
omission, underdose, and then wrong drug and wrong rate-too fast. (see Table15). 
 
Comparison of Computerized Monitoring and Voluntary Reporting 
When comparing the two periods of voluntary reporting, the top four drug 
categories; antibiotics, intravenous fluid, intravenous nutrition therapy, and narcotic 
analgesic were the same.  There were a total of seven therapeutic categories that were the 
same between the two time periods.  The other three categories being: antineoplastic, 
general anesthetic, and antifungal.  When these common categories were compared with 
the computerized monitoring ADE categories, three of the top four categories were in  
 
Table 15 
Preventable ADEs reported voluntarily during 2008 study time frame 
 





Dispensing Administration Monitoring Total 
Dose Omission 0 0 0 0 1 0 1 
Overdose 0 0 1 1 2 0 4 
Underdose 0 0 0 0 1 0 1 
IV Infiltration 0 0 0 0 78 0 78 
Wrong Drug 1 0 0 0 0 0 1 
Wrong Rate-
Too fast 
0 0 0 0 1 0 1 
Other 0 0 0 0 2 0 2 






common.  Those categories were: antibiotics, narcotic analgesic, and intravenous 
nutrition therapy.   
The increase in the number of detected ADEs during the study time frame in 2009 
(219 of 4,105 admissions) when compared with the same time frame in 2008 (87 of 3,830 
admissions) was found to be statistically significant (p < 0.0001). 
In looking at preventable ADEs, errors were most often associated with the 
administration stage of the medication ordering and delivery process in both the 
computerized monitoring tool and voluntary reporting.  Prescribing was the second most 
often associated stage for computerized monitoring, whereas dispensing was identified as 
the second most often associated stage between voluntary reporting.  The most often 
reported error type for computerized monitoring was overdose followed by infiltration, 
whereas voluntary reporting identified infiltration, then wrong drug and overdose as 
third. 
 
Triggers and Alerts 
Of the 83 triggers that were implemented at PCMC, there were 51 triggers that 
generated a total of 3,769 alerts in 1,424 patients over 1,590 admissions.  There were 25 
triggers that generated 233 alerts which pharmacy staff had marked as being associated 
with an ADE.  Of these 233 alerts, 181 were determined to be ADEs, while another 41 
were alerts that fired multiple times and were related to a previously identified ADE.  For 
example, a patient with a high phenytoin level, that was identified as an ADE, had two 
other levels reported over the next 3 days that were high, thus two additional alerts were 
generated related to the same event.  Of the remaining 11 alerts that were reported as 





admission, five were determined not to be an ADE upon further review, and one was an 
intentional overdose, and did not meet the criteria for inclusion in the study.  After 
removing these 41 alerts, was a total of 24 triggers that were associated in 181 ADEs (see 
Table 16) 
The Positive Predictive Value (PPV) of all triggers was 4.8 percent.  The PPV for 
triggers that identified at least one ADE ranged from 88.2 percent for the Wydase Trigger 
to 0.17 percent for the Respiratory trigger. 
There was an average of 44.9 triggers per day with a standard deviation of 17.9 
alerts per day.  The minimum number of alerts per day was eight and the maximum was 
78. 
Of the 11 new triggers that were added, eight fired a total of 406 alerts.  Table 17 
provides a summary of the performance of these new triggers as compared with the 
modified and unmodified triggers.  Five of these triggers were associated with a total of 
26 ADEs.  The PPV for the new triggers was 6.4 percent.  The most effective new 
triggers in order were Wydase ordered, Antifactor Xa level, Viokase 8 and Sodium 
Bicarbonate ordered, Tacrolimus level, and EOS level.  Those triggers which had alerts 
but no associated ADEs were Racemic Epinephrine ordered, Acetylcysteine ordered, and 
low dose Nubain ordered.  Those new triggers that did not alert during the study included 
caffeine level, hydrochloric acid ordered, and Phentolamine ordered. 
Of the 14 triggers that were modified, 12 generated a total of 1,873 alerts.  Of 
those, three were associated with 11 ADEs.  The PPV for the modified triggers was 0.6 
percent.  The WBC trigger was the most effective with a PPV of 8.7 percent, followed by 






Description of trigger results 
 
Name of Trigger Trigger Modifications Alerts ADEs PPV 
Wydase New 17 15 88.2% 
Potassium Unchanged 141 65 46.1% 
Anti-factor Xa New 5 2 40% 
Viokase 8 and Sodium Bicarbonate tablet New 5 2 40% 
Naloxone Unchanged 11 3 27.3% 
C. difficile Unchanged 46 9 19.6% 
Benadryl Unchanged 263 36 13.7% 
SBP < 80 Unchanged 15 2 13.3% 
Doubling of Cr Unchanged 54 6 11.1% 
Phenytoin Lvl Unchanged 11 1 9.1% 
WBC Modified 46 4 8.7% 
Vanco trough Unchanged 52 4 7.7% 
SBP < 100 Unchanged 25 1 4% 
Tacrolimus New 27 2 7.4% 
Gent trough Unchanged 42 3 7.1% 
SGPT Unchanged 64 4 6.3% 
PTT Unchanged 34 2 5.9% 
Glucose_50 Unchanged 68 3 4.4% 
Glucose_350 Unchanged 150 3 2% 
EOS New 268 5 1.9% 
Billirubin Unchanged 61 1 1.6% 
Hydrocortisone IV Unchanged 123 1 0.8% 
Heart rate Modified 763 6 0.8% 
Respiratory rate Modified 589 1 0.2% 
Acetylcysteine New 21  0 0% 
Activated charcoal Unchanged 2  0 0% 
ALK PHOS Unchanged 30  0 0% 
Alteplase Unchanged 51  0 0% 
Atropine Unchanged 27  0 0% 
Benztropine Unchanged 1  0 0% 
Cyclosporin Modified 9  0 0% 
Epinephrine Unchanged 37  0 0% 
Flumazenil Unchanged 1  0 0% 
Gent peak Modified 7  0 0% 
Haloperidol Unchanged 2  0 0% 
INR Unchanged 1  0 0% 
Loperamide Unchanged 40  0 0% 







   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
Table 16 (Continued)  
   
Name of Trigger  Alerts ADEs PPV 
Nubain New 7  0 0% 
Phenobarbital Modified 116  0 0% 
Phenobarbital Lvl Unchanged 5  0 0% 
Phenytoin Modified 32  0 0% 
Platelet count Modified 3  0 0% 
Prednisone Modified 280  0 0% 
Protamine Unchanged 11  0 0% 
Racemic epinephrine New 56  0 0% 
SGOT Unchanged 29  0 0% 
SPO2 Unchanged 29  0 0% 
Steroid cream Unchanged 50  0 0% 
Tobra peak Modified 24  0 0% 
Vanco peak Modified 2  0 0% 
Vitamin K Modified 2  0 0% 







Performance of new, modified, and unchanged triggers 
 
Trigger Status Triggers (%) Alerts (%) ADEs (%) PPV 
Unchanged 58 (69.9) 1,490 (39.5) 144 (79.6) 9.7% 
New 11 (13.3) 406 (10.8) 26 (14.4) 6.4% 
Modified 14 (16.9) 1,873 (49.7) 11 (6.1) 0.6% 
Total 83 3,769 181   
 
The heart rate trigger generated 763 alerts and the respiratory rate trigger generated 589 
alerts for a total of 1,352 alerts or 35.9 percent of all alerts. 
Of the remaining 58 triggers that were unchanged, 32 generated a total of 1,490 
alerts.  Sixteen of the 32 triggers were associated with 144 ADEs.  The PPV for this set of 
triggers was 9.7 percent.  The most effective triggers were Potassium, Naloxone ordered, 
C. Difficile, Benadryl ordered, and SBP < 80.  There were 26 triggers in this set that did 
not generate any alerts. 
 
Time Analysis of Alert Investigation  
Of the 181 ADEs found during the study timeframe using the computerized ADE 
monitor, 178 had a time recorded for how long it took to investigate the alert and then 
enter it into the Web Events system.  The average time was 10.4 minutes with a standard 
deviation of 18.3 minutes and a range of 1 minute to 30 minutes with one outlier of 240 
minutes.  If the outlier is not included, the average time of investigation is 9.1 minutes, 
with a standard deviation of 6 minutes.  The distribution of the amount of time it took to 
investigate alerts associated with an ADE can be seen in Figure 3.  
There were 3,484 alerts that were marked as not being involved in an ADE.  Of 






Figure 3.  Distribution of time to investigate ADE associated alerts 
 
average of 2.7 minutes with a Standard Deviation of 2.2 minutes to investigate each alert 
that was not associated with an ADE.  The time range of investigation was from one 
minute to 20 minutes. 
When both sets of alerts are combined, the average time to investigate an alert 
was 3.1 minutes with a standard deviation of 4.9 minutes. 
The average amount of time it took to enter an ADE into the Web-Event system 
was estimated to be three minutes.  The amount of time spent investigating alerts 
associated with an ADE minus the time it took to enter the ADE into the Web Event tool 
was compared to the 2.7 minutes spent investigating alerts not associated with an ADE.  
The comparison was completed on the results with the single outlier case of 240 minutes 
included.  With the single outlier included the average time of investigation for alerts 
associated with an ADE was 7.4 minutes.  The comparison was also made with the single 






























associated with an ADE was 6.1 minutes per alert.  In either comparison the amount of 
time to investigate a true ADE was significantly higher than the amount of time to 
investigate a non-ADE alert (p < 0.0001). 
There were a total of 52 alerts or 1.4 percent of the alerts where insufficient or no 
information was entered by the pharmacists.  This could have been the result of a busy 
work schedule and the pharmacist’s inability to research all of the alerts, or it could have 
just been an oversight on the pharmacist’s part, either investigating the alert and then not 
including the information or just accidentally bypassing the alert without reviewing it. 
It is also important to note that on at least one unit, the pharmacists were confused 
about the minimum reporting time for alert investigation.  This confusion was the result 
of at least one other active study within the pharmacy where input of time spent by the 
pharmacist involved was also required.  The minimum time requirement for that study 
was 5 minutes.  When discovered, the pharmacists were retrained to use 1 minute per 
alert for this study’s minimum investigation time.  As a result of the confusion, it was 
possible that the reported minimum time spent investigating alerts that were not involved 








This study had several objectives.  One of the key objectives was to compare the 
detection rate of the computerized ADE tool at Primary Children’s Medical Center to the 
current method of voluntary reporting.  As would logically be expected with the 
introduction of a second detection method, the result was a significant increase in the 
detection of ADEs (p < 0.0001) when compared with the same time frame for the 
previous year.  The reasoning for such a large increase in detection of ADEs is because 
the computerized ADE monitoring tool allowed every patient to be reviewed for the 
presence of known ADE indicators.  It was able to do this using discrete data that is 
stored within the electronic medical record.  This freed the pharmacy staff from having to 
complete manual chart review to find these indicators.  It thus enabled them to focus on 
patients where the likelihood of an ADE was increased, instead of spending time 
manually reviewing the patient’s record or having to wait for a clinician report of a 
possible ADE, as would have occurred with the voluntary reporting method.  Another 
interesting point to note is that the increase may be due in part to the low percentage of 
ADE overlap that has been found among the methods of voluntary reporting and 
computerized monitoring in several previous studies.  This overlap has previously been 
reported by most studies as being between 0.5 percent and 4.3 percent.  Using the results 
of this study we were unable to definitively determine the amount of potential overlap 





daily workflow of the pharmacists.  In order to detect any overlap we would have had to 
implement the monitoring tool in a separate, more limited setting, with a team of 
pharmacy staff that investigated and tracked ADEs independent of the floor pharmacists. 
Another key objective of this study was to implement the computerized ADE 
alerting tool into the daily workflow of the Pharmacy department without increasing the 
demand on pharmacy resources.  Within this study we were successfully able to show 
that a computerized ADE monitoring tool can be implemented into daily workflow 
without increasing pharmacy staff.  We were also able to show that it was sustainable 
over the course of the entire study.  With so much concern about the rising cost of 
healthcare and the amount of uncertainty in the current healthcare environment, the 
ability of an institution to provide increased monitoring and improved quality of care 
with minimal budgetary impact is becoming an absolute necessity.   
The ADE detection rate of 4.4 ADEs per 100 admissions or 9.9 ADEs per 1,000 
patient days using computerized monitoring as reported in this study was higher than that 
reported in the two previous pediatric studies which also used computerized 
monitoring.36,40  Those studies reported rates of 1.8 and 2.3 ADEs per 100 admissions 
and 1.6 and 6.6 ADEs per 1,000 patient days.  However, the rate of ADE detection in this 
study did correspond to the rates of detection reported in adult studies that also used 
computerized monitoring.  Those studies reported rates between two and 6.2 ADEs per 
100 patient admissions34,35,41-43 and 9.6 ADEs per 1,000 patient days.35  The difference in 
the ADE detection rate of this study compared with the detection rates of the previous 
two pediatric studies may be the result of the number of triggers used by the 





study had a total of 83 triggers as compared with the other two pediatric studies which 
had 57 and 31 triggers each.36,42  The difference in detection rates may have also been the 
result of differences in the triggers themselves.  The triggers used in this study, with the 
exception of the newly added triggers, have been refined and modified ever since first 
being reported in 1991.34  The difference in ADE detection rates were less likely to have 
been the result of different patient types treated, or patient acuity among the hospitals, 
since both of the other facilities were similar to PCMC in that they were tertiary care 
centers and had a wide variety of similar patient services available.36,40,56-58 
The amount of time it took to investigate an alert associated with an ADE was 6.1 
minutes.  This was significantly higher than the 2.7 minutes that it took to investigate an 
alert that was not associated with an ADE (p<0.0001).  This type of comparison has not 
previously been reported, and although the significant difference in investigation times 
may have just been assumed by many, it is still important to quantify just how much of a 
difference there is when investigating alerts that result in an ADE from alerts that do not. 
The amount of time that pharmacists spent investigating alerts was compared to 
other computerized monitoring studies where the amount of time spent by pharmacy staff 
was reported.35,36,40,43  Although, these studies did not specifically report the amount of 
time it takes to investigate an individual alert, there is enough information in the studies 
to extrapolate the data (Table 18).  The average investigation time extrapolated from the 
reported data was found to be from 1.7 to 8.9 minutes per alert.  From the results of this 
study we found that it took an overall average of 3.1 minutes to investigate an alert.  This 
result falls within the range found in the data extrapolated from the other studies.  



















Time per Alert 
Minutes 
Current Study 2/2/2009 4/26/2009 84 946 3679 3.1 
Kilbridge et al.40 2/1/2008 7/31/2008 182 420 1226 8.9 
Kilbridge et al.43 3/1/2005 4/30/2005 61 900-1500 4604 1.7-2.8 
Evans et al.50 5/1/1989 5/1/1990 365 600 4457 7.0 
Jha et al.35 10/1/1994 5/31/1995 243 660 2620 8.7 
 
admissions and 4.8 per 1,000 patient days during the study timeframe in 2009 and 2.5 per 
100 admissions and 5.3 per 1,000 patient days for the same time period in 2008) were 
compared against the two other pediatric studies that investigated computerized 
surveillance in addition to voluntary reporting.  The rates for Primary Children’s were 
higher than the 1.9 ADEs per 100 admissions and 1.8 ADEs per 1,000 patient days found 
in the study by Ferranti et al.36  This result could be the difference in definitions among 
the two studies.  The study by Ferranti et al36 used a seven point severity scoring system, 
where as we used the NCC MERP Index for Categorizing Medication Error in this 
study.24  It could also be a difference in interpretation of the definition of an ADE or even 
differences in the evaluation techniques among those individuals reviewing the events. 
The 11 new triggers added to the computerized ADE monitoring tool had an 
overall PPV of 6.4 percent.  Five of those triggers detected a total of 26 ADEs or 14.4 
percent of all ADEs detected via the computerized monitoring tool.  Of those five, three 
triggers had a PPV at or above 40 percent.  Refer to Table 17 for additional detail about 
the performance of new triggers and to Table 3 for a list of all 11 new triggers.  Four of 
the triggers will need to be reviewed further for modification to improve the PPV or to 





triggers and adding additional triggers that were determined to be beneficial to the 
pediatric population.  Many of these triggers may also be beneficial in the adult 
population as well.  The new triggers did not have as high a PPV as the 58 existing 
unmodified triggers, which had a PPV of 9.7 percent.  The difference in the PPV may be 
the result of modifications previously made in the adult tool over time to maximize the 
PPV, while the new triggers will still need additional modifications and refinement to 
maximize their PPV result values. 
Of the 14 triggers that were modified for pediatrics, only three were associated 
with a total of seven ADEs.  The WBC trigger had the highest PPV of 8.7 percent while 
the heart rate respiratory rate triggers both had disappointing performances with PPVs 
less than 1 percent each..  The pharmacists reported that the heart rate and respiratory rate 
triggers were the two most cumbersome of all the triggers that generated alerts.  This was 
because of the extremely high false positive rate of these two triggers.  They generated 
35.9 percent of the alerts but only accounted for 3.9 percent of the ADEs.  The high false 
positive rate of these two triggers was the result of only limiting the trigger criteria to age 
specific values.  It is clear that additional modifications will need to be made for these 
two triggers in order to increase the PPV.  In addition, the pharmacists expressed that if 
these two triggers could be modified to filter out a large number of the false positives, the 
tool would be more acceptable.  Modified triggers that need to be reviewed for further 
modification or removal include Heart Rate, Respiratory Rate, Prednisone, Phenytoin 
ordered, Phenobarbital ordered, WBC, and Tobra Peak. 
A determination was made that depletion of electrolytes severe enough to cause 





harm to the patient and was therefore considered an ADE.  The number of ADEs detected 
in our study with the low potassium trigger represented 35.9 percent of all ADEs found 
using computerized ADE monitoring.  This definition and the subsequent results are 
similar to that of Kilbridge et al.40 which found 66 ADEs of 223 alerts (PPV 30 percent) 
with their Hypokalemia trigger and represented 41 percent of the ADEs found during 
their study.  These results may simply be the outcome of this definition being applied to 
represent an ADE in this study, where it has not been delineated as such in other studies.  
In order to determine if the results of this trigger represents a significant difference in 
ADE detection between pediatrics and adults, more investigation will need to be 
completed by applying the same definition to the adult population to determine how often 
the same situation occurs.  Also, more investigation needs to be completed to determine 
how often this situation occurs when patients are receiving potassium wasting 
medications and if there is predictability to its occurrence.  If this can be determined there 
is potential that it can be prevented from occurring. 
Only two ADEs were categorized as an “F” on the NCC MERP scale out of 181 
ADEs found using computerized monitoring.  This is consistent with the number of 
ADEs categorized as “F” found via voluntary reports during the same time frame in 2009 
(1 out of 88 ADEs) and during the same time period in 2008 (1 of 96 ADEs).  That ratio 
is less than was found by Kilbridge et al.42 in which 20 out of 160 ADEs detected were 
categorized as “F” with another five being categorized between “G” and “I.”  This 
finding may have been the result of preventative methods already in place at the study 





chance since the time frame of this study was only three months versus the six months for 
the study reported by Kilbridge et al.40 
The overall percentage of preventable ADEs found during the study period via 
voluntary reporting and computerized monitoring was 31 percent.  This finding is within 
the range of 19 and 61 percent found among previous pediatric studies.9,10,39  The 
pediatric studies that reported rates of preventable ADEs used the method of intensified 
surveillance or a manual trigger tool conducted via manual chart review. 
When we looked at the methods separately, it was clear that voluntary reports 
were more likely to capture preventable ADEs (p<0.0001) with 72.7 percent of voluntary 
reports from the study time frame and 89.6 percent of voluntary reports from the same 
time period in 2008 being identified as preventable.  These rates were higher than what 
was found in the pediatric studies previously mentioned.  This high rate is likely the 
result of IV infiltrations being considered a preventable ADE at the study facility.   
Computerized surveillance captured more unpreventable ADEs with only 10.5 
percent of the computerized surveillance ADEs being considered preventable.  Ferranti et 
al. also reported that their voluntary reporting system was better at detecting system 
failures like drug omission, administration errors, and lapses in monitoring than 
computerized surveillance.36  Neither of the pediatric studies that used computerized 
surveillance reported the rate of preventable ADEs found using that method.  In adults, 
Jha et al. reported that 25.5 percent of ADEs found using computerized surveillance in 
their study were deemed to be preventable.  However, they did not report any further 
detail regarding how these events occurred.  Classen et al. reported that they felt almost 





percent of all their ADE’s were the result of excessive medication dosage for the patient’s 
weight and calculated renal function and that these were felt to be preventable.  They also 
reported that 4.6 percent of ADEs found in their study were the result of drug interactions 
and another 1.5 percent were the result of known drug allergies, both of which were felt 
to be preventable.  During the current study’s timeframe, the pharmacy system had many 
triggers that were specific to weight based dosing for pediatrics, drug interactions, and 
patient allergies.  These triggers fired at the time the pharmacist entered the order into the 
system and are part of the preventative methods mentioned in the methods section.  Thus, 
it is probable that most of the ADEs that were found to be preventable in the study by 
Classen et al. were prevented from occurring in this study.  This reasoning would explain 
why ADEs found via computerized monitoring only had a preventable rate of 10.5 
percent. 
Of the preventable ADEs, the most common Drug Ordering and Delivery Process 
stage identified was administration, followed by prescribing, dispensing, order review, 
and order processing.  This outcome was different than what was found in the Adverse 
Drug Event Prevention Study Group.37,45  That group found that errors in their studies 
occurred most often in physician ordering, followed by nurse administration, pharmacy 
dispensing, and then transcription and verification.  It is also different from what was 
found in the pediatric study by Takata et al.39 which reported that the most common error 
occurred in the monitoring stage followed by prescribing and dispensing.  Both the adult 
and pediatric studies37,39,45 were conducted using the intensified surveillance method.  
However, the pediatric study39 did include the use of a manual trigger tool.  The 





most common Drug Ordering and Delivery Process stages among the studies.  It may also 
be the result of the type of ADEs that were included in this study as compared to the 
other studies mentioned. 
There are several limitations to this study.  We did not complete inter-rater 
reliability testing because this study was implemented into the daily workflow of the 
pharmacy department and the large number of different pharmacists who were reviewing 
alerts made it impractical.  We did, however, have a second pharmacist review every 
positive ADE to validate the first pharmacist’s findings.  Due to cost and availability of 
resources, we did not conduct a concurrent chart review and therefore cannot compare the 
results of our study against the traditional gold standard.  In addition, this study was 










Prior to the initiation of this study there was little research that had been 
completed on ADEs in pediatrics, and no research on implementation of computerized 
surveillance to detect ADEs in pediatrics was discovered.  Since the initiation of this 
study, two other studies have been published that report results on the implementation of 
computerized ADE surveillance tool in pediatrics.  The results of this study reinforce 
those found in the other two studies and will continue to help lay the foundation for 
further study of the potential that computerized surveillance has for detecting ADEs in 
the pediatric population.  By continuing to research ADEs in the pediatric population: 
triggers can be more thoroughly modified and defined to increase the PPV, additional 
detail can be discovered about the presence and relationship of pediatric ADEs resulting 
from potassium wasting medications, and more detail about the occurrence of this type of 
ADE in the adult population and the relationship to the pediatric population can be 
explored.  The long term outcomes of continuing research ADEs in the pediatric 
population are that methods can be implemented that will help to reduce the amount of 
harm that pediatric patients undergo as a result of ADEs.  In addition, it will also help to 
reduce the cost of healthcare in this population. 
This study undertook the challenge of modifying an adult computerized ADE 





modified tool significantly increased the detection of ADEs among the pediatric 
population when compared to voluntary reporting and reinforces previous reports that 
many ADEs go unreported and or unrecognized.  The computerized surveillance of 
ADEs has previously been shown to be complementary to voluntary ADE reporting.   
The results of this study describe in more detail than has previously been reported, 
the amount of time it takes to investigate alerts.  The results also show that there was a 
significant difference if the alert identified an ADE.  In addition,  computerized 
surveillance detects fewer ADEs that are preventable or are the result of error. 
The results of this study suggest that the types of ADEs that occur in children may 
be different than those that occur in adults.  However further research is needed in order 
to make any conclusion on this point with confidence. 
Work needs to continue on the modification of trigger rules to increase the PPV of 
each trigger in order to ensure that it is viewed as a beneficial tool in improving the 
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